Neurophet Launches Comprehensive Alzheimer’s Disease Treatment Solution “Neurophet AQUA AD” at AAIC 2024

– Demonstrates Neurophet AQUA AD in AD treatment such as Leqembi and Kisunla

– Introduced updated version of Neurophet SCALE PET with centiloid scale function

Seoul, South Korea, July 25, 2024 /PRNewswire/ — Neurophet, a company offering artificial intelligence (AI) solutions for brain diseases, announced its participation in the Alzheimer’s Association International Conference (AAIC 2024), which will be held in Philadelphia, USA

At the upcoming AAIC, Neurophet will launch “Neurophet AQUA AD”, a software for prescribing Alzheimer’s disease (AD) drugs and monitoring treatment effects and side effects. Neurophet AQUA AD is an integrated solution of cutting-edge brain image analysis technology related to AD treatment. This solution is currently preparing for medical device certification in Korea, the U.S. and Japan.

Neurophet will present Neurophet AQUA AD and the PET brain image analysis software “Neurophet SCALE PET” with updated key features at the company’s booth.

The Alzheimer’s disease treatment market is set to boom following this month’s FDA approval of Eli Lilly’s newest Alzheimer’s drug Kisunla (donanemab), a follow-on to Leqembi (lecanemab) developed by global pharmaceutical company Eisai. Japan and Biogen in the US

Anti-amyloid treatments such as Kisunla and Leqembi carry a warning about the risk of amyloid-related imaging abnormalities (ARIA), which are known adverse events such as edema and microhemorrhages. In fact, ARIA has been reported in 20% to 30% of patients in clinical trials of both treatments. Patients undergoing anti-amyloid therapy must undergo MRI scans at least 5 to 6 times per year to monitor ARIA.

Neurophet AQUA AD is a software that provides all the brain imaging biomarker analysis features required during the administration of anti-amyloid drugs, through quantitative analysis of MRI and PET images. It is possible to determine patient eligibility for treatment before administration, monitor ARIA during administration and analyze the effects of treatment due to the reduction of amyloid beta deposition in the brain.

In addition, Neurophet will introduce a significantly updated version of Neurophet SCALE PET with a centiloid scale feature. The centiloid scale quantifies the positivity and negativity of amyloid PET images and standardizes amyloid plaque deposition from 1 to 100 in amyloid PET, even when different tracers are used.

“We are excited to present our groundbreaking, comprehensive solution for the treatment of AD at AAIC, a global conference that brings together scientists from around the world,” said Neurophet CEO Jake Junkil Been. “We expect the use of Neurophet AQUA AD, a specialized technology for brain imaging analysis, in the context of treating AD to be extremely high.”

AAIC is the world’s largest conference for the advancement of dementia research, bringing together researchers, clinicians, and dementia specialists to share research and clinical practice on diagnosing, reducing risk, and improving treatment for AD and other types of dementia. AAIC is held at Philadelphia, USA this year which starts July 28 (local time) and lasts until August 1^saint.

About Neurophet

Neurophet specializes in developing diagnostic support solutions, treatment guides, and therapeutic devices for brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed a next-generation neuronavigation system.

Key products include magnetic resonance imaging brain analysis software “Neurophet AQUA”, PET brain image analysis software (PET tracer embedding) “Neurophet SCALE PET”, brain imaging treatment planning software using electrical and magnetic stimulation “Neurophet tES/TMS LAB”.

Neurophet has made it its top priority to help patients suffering from brain diseases. Based on its expertise in neuroscience, Neurophet will continue to challenge and evolve to study human brain health and pioneer AI-based solutions for brain diseases.

Source :Neurophet Launches Comprehensive Alzheimer’s Disease Solution “Neurophet AQUA AD” at AAIC 2024

The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Business News.